We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Expanded access is currently available for this treatment.
Verified October 2017 by Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
First Posted: September 20, 2013
Last Update Posted: October 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
September 17, 2013
September 20, 2013
October 26, 2017
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.
Not Provided
Expanded Access
, Treatment IND/Protocol
Drug: LDK378
750 mg. orally
Not Provided
Contact: Novartis Pharmaceuticals 1-888-669-6682 Novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111
Argentina,   Colombia,   Hong Kong,   India,   Jordan,   Korea, Republic of,   Mexico,   Philippines,   Thailand,   United States
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Not Provided
October 2017